• Home
  • About YZYBIO
    Company Overview Leadership Team Milestones Contact Us
  • Science and Technology
    Research Area Technology Platforms Product Pipeline Production Operation Partnerships Publication
  • Products and Research
    RD Center Scientific Progress
  • Investor Relations
    Corporate Governance Information Disclosure IR Calendar Presentation and Webcast Press Release Paperless Corporate Communications
  • News
    Press Release Media Report
  • Careers
    Corporate Culture Careers Development

中文

  • Home
  • About YZYBIO
    About YZYBIO Company Overview Leadership Team Milestones Contact Us
  • Science and Technology
    Science and Technology Research Area Technology Platforms Product Pipeline Production Operation Partnerships Publication
  • Products and Research
    Products and Research RD Center Scientific Progress
  • Investor Relations
    Investor Relations Corporate Governance Information Disclosure IR Calendar Presentation and Webcast Press Release Paperless Corporate Communications
  • News
    News Press Release Media Report
  • Careers
    Careers Corporate Culture Careers Development
  • 简体 English
News
Witness our development together
TOP10!友芝友生物制药获第六届中国生物医药创新合作大会最具成长性抗体药企业TOP10!
  • 2022-08-05 09:21:00
  • 2558

 

2022年8月4日,武汉友芝友生物制药股份有限公司(以下称“友芝友生物制药”)获2022第六届中国生物医药创新合作大会暨2022中国生物医药产业价值榜颁奖盛典“最具成长性抗体药企业TOP10”荣誉称号。

 

 

第六届中国生物医药创新合作大会由万怡医学、北京医学奖励基金会联合主办,大会BIO-PHARM2022组委会联合华医研究院结合竞争要素、商业化要素、价值要素、战略要素、产品要素、团队要素等多个维度进行判断,对行业、产业、企业深度测评,形成“2022中国生物医药产业价值榜”。

 

本次大会抗体创新药榜单主要聚焦具有抗体创新药管线且研发进展相对领先的企业,友芝友生物制药专注于双特异性抗体药物的研发与产业化,现有十余个在研产品,覆盖肿瘤、感染和老年退行性疾病等多个领域,并建立了一个完整的抗体药物开发产业链。未来,友芝友生物制药将继续加大研发投入,大力引进和培养人才,广泛开展技术交流与合作,为推进抗体药研发工作做出更多贡献。

 

相关链接:

重磅开幕!第六届中国生物医药创新合作大会暨2022中国生物医药产业价值榜颁奖盛典成功召开!

Pren:友芝友生物完成B-2轮融资
Next:友芝友生物制药与康哲药业达成靶向VEGF和ANG2的四价双特异性抗体全球合作
Back
Hot
  • 2022-12-12
    科研进展 | JITC(IF: 12.5):友芝友生物双特异性抗体(抗TGF-β/PD-L1)在三阴性乳腺癌模型上取得科研新进展
    View more
  • 2022-12-07
    合床试验许可:PD-L1/TGF-β双特异性抗体(Y101D)联合用药一线治疗胰腺癌临床试验获得许可
    View more
  • 2022-10-11
    J Hematol Oncol.(IF: 23.168):基于友芝友生物研发的双抗体YM101的联合免疫治疗方案取得科研新进展
    View more
Home About YZYBIO Science and Technology Products and Research Investor Relations News Careers
Phone:
027-82668988

E-Mail:info@yzybio.com

Address:Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China

Share
Copyright ©2014-2022 YOUZHIYOU All rights reserved 鄂ICP备2022016887号-1